Published in final edited form as:

Mol Neurobiol. 2013 February ; 47(1): 290–301. doi:10.1007/s12035-012-8350-1.

Nuclear lamins in the brain—new insights into function and regulation

Hea-Jin Jung¹, John M. Lee², Shao H. Yang², Stephen G. Young^{1,2,3,*}, and Loren G. Fong^{2,*}

¹Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA

²Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA

³Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA

Abstract

The nuclear lamina is an intermediate filament meshwork composed largely of four nuclear lamins—lamins A and C (A-type lamins) and lamins B1 and B2 (B-type lamins). Located immediately adjacent to the inner nuclear membrane, the nuclear lamina provides a structural scaffolding for the cell nucleus. It also interacts with both nuclear membrane proteins and the chromatin and is thought to participate in many important functions within the cell nucleus. Defects in A-type lamins cause cardiomyopathy, muscular dystrophy, peripheral neuropathy, lipodystrophy, and progeroid disorders. In contrast, the only *bona fide* link between the B-type lamins and human disease is a rare demyelinating disease of the central nervous system—adult-onset autosomal-dominant leukoencephalopathy, caused by a duplication of the gene for lamin B1. However, this leukoencephalopathy is not the only association between the brain and B-type nuclear lamins. Studies of conventional and tissue-specific knockout mice have demonstrated that B-type lamins play essential roles in neuronal migration in the developing brain and in neuronal survival. The importance of A-type lamin expression in the brain is unclear, but it is intriguing that the adult brain preferentially expresses lamin C rather than lamin A, very likely due to microRNA-mediated removal of prelamin A transcripts. Here, we review recent studies on nuclear lamins, focusing on the function and regulation of the nuclear lamins in the central nervous system.

Keywords

Nuclear lamina; brain development; A-type lamins; B-type lamins; differential gene expression

Introduction

The nuclear lamina is an intermediate filament meshwork located adjacent to the inner nuclear membrane. In vertebrates, it is composed largely of four proteins called nuclear lamins—lamins A, C, B1, and B2 [1]. The lamins have been classified as A- and B-type based on their biochemical properties [2–4]. The expression of the A-type lamins (lamins A and C) starts during the later stages of embryonic development and peaks postnatally; B-

*Correspondence: Loren G. Fong, Ph.D. or Stephen G. Young, M.D., 650 Charles E. Young Dr. South, Los Angeles, CA 90095, USA. Tel: (310) 825-4934; Fax: (310) 206-0865; lfong@mednet.ucla.edu, sgyoung@mednet.ucla.edu.

CONFLICT OF INTEREST STATEMENT

None declared.

type lamins (lamins B1 and B2) are expressed in all cell types from the earliest stages of development [5, 6].

Lamins A and C are alternatively spliced products of the same gene, *LMNA* (Figure 1) [7]. They are identical through the first 566 amino acids but diverge in their carboxyl-terminal domains. Lamin C terminates with exon 10 sequences and has 6 unique amino acids (not found in lamin A) at its carboxyl terminus. Prelamin A, the precursor to mature lamin A, includes sequences from two additional exons (exons 11 and 12), resulting in 98 unique amino acids at its carboxyl terminus. The 3' UTRs of lamin C and prelamina A transcripts are also distinct. Lamin C's 3' UTR, formed by intron 10 sequences, is short (~100 bp); prelamina A's 3' UTR is ~1 kb in length and includes many sequences that have been conserved through mammalian evolution.

Lamins B1 and B2, are encoded by distinct genes, *LMNB1* [8] and *LMNB2* [9], respectively. These genes have a similar intron–exon structure, suggesting that they arose from a gene-duplication event [1, 10]. Lamin B1 and lamin B2 proteins are ~60% identical at the amino acid level [11].

Like other intermediate filament proteins, all nuclear lamins have a highly conserved α -helical central rod domain (Figure 1) [12, 13]. The rod domain is critical for lamin dimerization and for the formation of higher-order polymers [14]. Lamins also have globular head and tail domains, with the tail domain containing a nuclear localization signals (NLS) (Figure 1) [12, 13].

Physiologic importance of A-type lamins

To assess the importance of the A-type lamins, Sullivan and coworkers [15] generated *Lmna* knockout mice (*Lmna*^{−/−}). *Lmna*^{−/−} mice do not manifest developmental abnormalities and are indistinguishable from wild-type littermates at birth [15]. Soon thereafter, however, *Lmna*^{−/−} mice develop a cardiac and skeletal myopathy, and they die by 6–8 weeks of age. The absence of A-type lamins compromises the structural integrity of the nuclear envelope, resulting in misshapen nuclei, which likely plays a part in the pathogenesis of the muscle disease [16]. The absence of lamins A and C also results in mislocalization of emerin, an inner nuclear membrane protein, to the endoplasmic reticulum. Emerin mutations cause muscular dystrophy in humans [2, 17–19].

Thus far, *unique* roles for lamin A and lamin C remain obscure. Fong *et al.* [20] created “lamin C–only mice” (*Lmna*^{LCO/LCO}) that do not produce prelamina A transcripts and make approximately twice-normal amounts of lamin C transcripts. Surprisingly, the absence of prelamina A and lamin A in *Lmna*^{LCO/LCO} mice does not appear to have adverse consequences; these mice are normal in size and vitality and have no obvious disease phenotypes. Subtle abnormalities in nuclear shape can be detected in cultured *Lmna*^{LCO/LCO} fibroblasts [16, 20], but it is unclear whether any such abnormalities actually occur in parenchymal cells of *Lmna*^{LCO/LCO} mice. Later, Coffinier *et al.* [21] generated “mature lamin A–only mice” (*Lmna*^{LAO/LAO}) and Davies *et al.* [22] created “prelamina A–only mice” (*Lmna*^{PLAO/PLAO}). Both mouse models are incapable of producing lamin C transcripts, and all of the output of the *Lmna* gene is channeled into prelamina A transcripts (encoding mature lamin A in the case of *Lmna*^{LAO/LAO} mice or full-length prelamina A in *Lmna*^{PLAO/PLAO} mice). The *Lmna*^{LAO/LAO} and *Lmna*^{PLAO/PLAO} mice are healthy and free of pathology. Misshapen nuclei can be observed in cultured *Lmna*^{LAO/LAO} fibroblasts but were never observed in the tissues of *Lmna*^{LAO/LAO} mice [21].

Prelamin A contains a “*CaaX*” motif at its carboxyl terminus (Figure 1), which triggers three sequential posttranslational *CaaX* processing steps: farnesylation of a carboxyl-terminal

cysteine (the “C” of the *CaaX* motif), cleavage of the last three amino acids of the protein (*i.e.*, the “-aaX”), and carboxyl methylation of the newly exposed farnesylcysteine [23, 24]. Prelamin A undergoes one additional processing step: cleavage of the last 15 amino acids of the protein, including the carboxyl-terminal farnesylcysteine methyl ester. This final step, carried out by the metalloprotease ZMPSTE24, releases mature lamin A. Lamin C does not have a *CaaX* motif and does not undergo any of these posttranslational processing steps.

Protein farnesylation and methylation have been assumed to be important for the association of the nuclear lamins with the inner nuclear membrane. This notion has been supported by *in vitro* evidence [25] but the *in vivo* relevance of these modifications remained uncertain until the development of *Lmna*^{LAO/LAO} mice [21]. *Lmna*^{LAO/LAO} mice, which produce mature lamin A *directly*—completely bypassing prelamina A synthesis and processing—are phenotypically normal. The levels of mature lamin A in cells and tissues are normal, and there is no significant defect in the ability of lamin A to reach the nuclear rim. Thus, the posttranslational processing of prelamina A is quite dispensable, at least in laboratory mice.

While the posttranslational processing of prelamina A appears to be dispensable, it is important to emphasize that *defects in prelamina A processing can elicit severe disease*. For example, ZMPSTE24 deficiency abolishes the final endoproteolytic cleavage event in lamin A biogenesis, leading to an accumulation of farnesyl–prelamin A in cells and progeria-like disease phenotypes—both in humans and in mice [26–29]. These disease phenotypes can be eliminated by reducing prelamina A synthesis with a single *Lmna* knockout allele [30] or a single *Lmna*^{LCO} allele [20], clearly demonstrating that farnesyl–prelamin A was responsible for disease. Also, the classic progeroid syndrome of children, Hutchinson–Gilford progeria syndrome, is caused by a *LMNA* mutation that prevents the conversion of farnesyl–prelamin A to mature lamin A [31, 32]. Finally, abolishing *all* prelamina A processing steps leads to cardiomyopathy, as illustrated by a gene-targeted mouse model by Davies *et al.* [22]. They created a “nonfarnesylated prelamina A-only” mouse (*Lmna*^{nPLAO/nPLAO}) by replacing the cysteine in prelamina A’s *CaaX* motif with a serine. In *Lmna*^{nPLAO/nPLAO} mice, prelamina A does not undergo farnesylation, nor does it undergo any of the subsequent posttranslational processing steps. The nonfarnesylated prelamina A in *Lmna*^{nPLAO/nPLAO} mice is targeted quite normally to the nuclear rim, indistinguishable from mature lamin A in wild-type mice, but the *Lmna*^{nPLAO/nPLAO} mice develop a dilated cardiomyopathy and die by 6–8 months of age [22].

Physiologic importance of B-type lamins in mammalian cells

The B-type lamins have been assumed, based on *in vitro* studies [33–37], to be essential in eukaryotic cells, with unique and vital roles in DNA replication, the formation of the mitotic spindle, gene transcription, and a variety of other processes in the cell nucleus. However, until recently, the importance of B-type lamins had never been tested *in vivo* with appropriate mouse models. Yang *et al.* [38, 39] generated *Lmnb1* and *Lmnb2* conditional knockout alleles, making it possible to eliminate B-type lamins in specific cell types. Remarkably, the loss of both lamin B1 and B2 in skin keratinocytes has no perceptible effect on keratinocyte growth or on the complex developmental programs involved in the generation of the skin and adnexal structures. Misshapen nuclei can be observed in *Lmnb1/Lmnb2*-deficient keratinocytes in culture, but misshapen nuclei were never found within the skin of the keratinocyte-specific *Lmnb1/Lmnb2*-deficient mice [38]. Similarly, the loss of B-type lamins has no adverse effects on liver hepatocytes [39]. These studies suggest that B-type lamins are dispensable, at least in some cell types, and raise doubts about whether the B-type lamins truly have *unique* roles in mitosis, DNA replication, *etc.* Of note, skin keratinocytes and hepatocytes express A-type lamins; thus, it is possible that the nuclear

lamin proteins have redundant roles in the cell nucleus and the A-type lamins are able to compensate for the loss of both B-type lamins.

Kim *et al.* [40] recently showed that B-type lamins are dispensable in embryonic stem cells. The authors derived ES cells lacking both *Lmnb1* and *Lmnb2* and found that the cells grew normally and could be differentiated to trophectoderm cells with an efficiency similar to that of wild-type ES cells. Lamin A and lamin C were undetectable in undifferentiated ES cells by routine western blots or conventional RT-PCR [40]. However, in our hands, low but easily detectable levels of *Lmna* transcripts are present in pluripotent undifferentiated ES cells, as judged by quantitative real-time RT-PCR (unpublished observations); hence, it remains possible that low levels of A-type lamins in ES cells compensate for the absence of B-type lamins.

Both lamin B1 and lamin B2 terminate with a *CaaX* motif (Figure 1) and undergo farnesylation, endoproteolytic cleavage of the last three amino acids, and methylation of the farnesylcysteine. Unlike prelamin A, however, there is no additional endoproteolytic cleavage step; thus, the B-type lamins retain their carboxyl-terminal farnesylcysteine methyl ester. For both lamin B1 and lamin B2, the physiological relevance of the carboxyl-terminal posttranslational processing events is uncertain and needs to be investigated by creating knock-in mice that express nonfarnesylated versions of these proteins.

A role for B-type lamins in brain development

The essential role of B-type lamins in the developing brain was first uncovered by Coffinier *et al.* [41] during the characterization of lamin B2-deficient mice (*Lmnb2*^{-/-}). *Lmnb2*^{-/-} mice die at birth; however, newborn *Lmnb2*^{-/-} mice are normal in size and there are no histopathological abnormalities in any organs, except for the brain. The brain in *Lmnb2*^{-/-} mice is slightly smaller than normal, and there is a striking defect in the layering of neurons within the cerebral cortex. Subsequent studies of *Lmnb2*^{-/-} embryos revealed a defect in the migration of neurons from the ventricular zone to the cortical plate. The neuronal migration defect was documented both by BrdU birthdating experiments and immunohistochemical studies with cortical layer-specific markers [41]. The development of the cerebellum is also profoundly abnormal in *Lmnb2*^{-/-} embryos, with a complete absence of foliation and an absence of a discrete Purkinje cell layer. The layering of neurons in the hippocampus is also perturbed in *Lmnb2*^{-/-} embryos [41].

Occasional neurons in the cortical plate of *Lmnb2*^{-/-} embryos have “comet-shaped” nuclei with detached centrosomes (located >20 μm from the cell nuclei) (Figure 2a) [42]. These “stretched out” nuclei were never observed in wild-type brains. Lamin B1 remains uniformly distributed at the nuclear rim in *Lmnb2*^{-/-} neurons.

We proposed that the “stretched out” nuclei in *Lmnb2*^{-/-} neurons are likely a consequence of the deformational stresses associated with nucleokinesis during neuronal migration [43, 44]. A crucial step in neuronal migration is pulling the cell nucleus forward (by cytoplasmic motors) toward the centrosome in the direction of the leading edge of the cell [43, 44]. We suspect that the structural integrity of the nuclear envelope is compromised by the absence of lamin B2 (particularly since there is little or no *Lmna* expression in neurons during development) [42]. We have suggested that the same forces that are meant to pull the nucleus forward are responsible for “stretching out” the nucleus (creating the distinctive comet-shaped nucleus) in *Lmnb2*^{-/-} neurons [42–44].

Lmnb2^{-/-} embryonic fibroblasts exhibit few abnormalities; *Lmnb2*^{-/-} fibroblasts grow normally and do not exhibit aneuploidy [41]. Staining of *Lmnb2*^{-/-} embryonic fibroblasts

with antibodies against several nuclear envelope proteins did not uncover abnormalities in nuclear shape [41].

After uncovering a role for lamin B2 in the developing brain, Coffinier and coworkers were interested in ascertaining the importance of lamin B1 in brain development [42]. In approaching this problem, they built on earlier studies by Vergnes *et al.* [45], who had generated lamin B1-deficient mice (*Lmnb1*^{Δ/Δ}) with a gene-trap ES cell clone. *Lmnb1*^{Δ/Δ} mice synthesize a lamin B1-βgeo fusion protein that lacks a large fraction of the lamin B1 coding sequences, including two known phosphorylation sites, the nuclear localization signal, and the carboxyl-terminal CaaX motif [45]. *Lmnb1*^{Δ/Δ} mice were abnormally small during development and died shortly after birth, with abnormalities in lung and bones [45]. In the work by Vergnes and coworkers, the possibility of neuropathology was not specifically investigated, but the authors did note that the calvarium in *Lmnb1*^{Δ/Δ} mice was abnormally flattened and that these mice had abnormalities in the cranial sutures [45]. Interestingly, *Lmnb1*^{Δ/Δ} embryonic fibroblasts in culture had misshapen nuclei and exhibited a reduced replication rate, polyploidy, and premature senescence [45].

When Coffinier *et al.* [42] examined the brains of *Lmnb1*^{Δ/Δ} embryos, they found that the characteristic layering of neurons in the cerebral cortex is markedly abnormal. Using a combination of BrdU birthdating and immunohistochemistry studies, they showed that the neuronal layering defect is due to defective neuronal migration. They also found that the cortical plate of *Lmnb1*^{Δ/Δ} embryos is abnormally thin, with fewer neuronal progenitor cells and more apoptotic cells, implying a defect in neuronal survival. The cerebellum of *Lmnb1*^{Δ/Δ} embryos is small and devoid of foliation.

In *Lmnb1*^{Δ/Δ} embryos, many of the neurons in the cortical plate contain a solitary nuclear bleb. Also, lamin B2 is asymmetrically distributed at the nuclear rim, with a large fraction of the lamin B2 being located at the rim of the nuclear bleb (Figure 2b) [42]. The authors suggested that the solitary bleb might be the consequence of the deformational forces that occur with nucleokinesis during neuronal migration [42]. We have observed the same “solitary nuclear blebs” in cells of peripheral tissues of *Lmnb1*^{Δ/Δ} embryos (unpublished observations), raising the possibility that deformational forces on cell nuclei could exist in peripheral tissues as well.

To investigate the role of the B-type lamins in the postnatal brain, Coffinier *et al.* [42] took advantage of a forebrain-specific *Cre* transgene (*Emx1-Cre*) [46] and conditional knockout alleles for *Lmnb1* and *Lmnb2* [38] to create forebrain-specific *Lmnb1* and *Lmnb2* knockout mice (*Emx1-Cre Lmnb1*^{fl/fl} and *Emx1-Cre Lmnb2*^{fl/fl}, respectively). Immunohistochemical studies showed that the knockout mutations worked as planned; ~90% of the cells in the cortical plate of *Emx1-Cre Lmnb1*^{fl/fl} and *Emx1-Cre Lmnb2*^{fl/fl} embryos have no lamin B1 or lamin B2, respectively. Both forebrain-specific knockout mouse strains are viable, and by four months of age, *Emx1-Cre Lmnb1*^{fl/fl} and *Emx1-Cre Lmnb2*^{fl/fl} mice exhibit a markedly smaller forebrain, suggesting that the postnatal survival of neurons is impaired (Figure 2c). Mice lacking both lamin B1 and lamin B2 in the forebrain (*Emx1-Cre Lmnb1*^{fl/fl} *Lmnb2*^{fl/fl}) were also generated. In *Emx1-Cre Lmnb1*^{fl/fl} *Lmnb2*^{fl/fl} embryos, it is possible to identify neurons lacking both lamin B1 and lamin B2. However, in adult *Emx1-Cre Lmnb1*^{fl/fl} *Lmnb2*^{fl/fl} mice, the forebrain is completely atrophic (Figure 2c); the thin layer of tissue representing the forebrain does not contain neurons, nor does it contain any cells lacking lamins B1 and B2. Thus, it would appear that neurons in the adult brain do not survive in the absence of both B-type lamins.

Misshapen cell nuclei are common in forebrain neurons of *Emx1-Cre Lmnb1*^{fl/fl} and *Emx1-Cre Lmnb2*^{fl/fl} embryos. Many neurons in *Emx1-Cre Lmnb1*^{fl/fl} embryos contain a solitary

nuclear bleb, and comet-shaped nuclei are observed in neurons of *Emx1-Cre Lmnb2^{fl/fl}* embryos. Interestingly, however, few of the neurons in the forebrain of *adult Emx1-Cre Lmnb1^{fl/fl}* and *Emx1-Cre Lmnb2^{fl/fl}* mice are misshapen, perhaps because neurons of the adult brain (unlike the neurons of embryos) express lamin C [42, 47].

In a recent study, Kim *et al.* [40] suggested that B-type lamins might have redundant roles in interkinetic nuclear migration. They found that neuronal progenitor cells containing phospho-histone H3 (a marker for G2/M phase cells) in the brains of *Lmnb1* and *Lmnb2* single knockout mice (at E14.5) are located normally in the apical portion of ventricular zone, whereas the neuronal progenitor cells in the brains of *Lmnb1/Lmnb2* double knockout mice are scattered along the basal side of ventricular zone.

At this point, we know that both lamin B1 and lamin B2 are crucial for brain development and postnatal neuron survival [41, 42]. We also know that the neuropathology in the lamin B2-deficient mice is distinct from that in lamin B1-deficient mice [41, 42]. Lamin B1 deficiency has a greater impact on the size and cellularity of the cortical plate than lamin B2 deficiency [42]. Also, the nuclear shape abnormalities in lamin B1- and lamin B2-deficient neurons are distinct. However, these observations do not provide clear-cut insights into whether lamin B1 and lamin B2 have functionally redundant roles in the development of the brain; additional knock-in mouse models will be required to address this issue. For example, it would be informative to generate a mutant mouse in which the lamin B1 coding sequences are “knocked in” to the *Lmnb2* locus, thereby replacing the production of lamin B2 with lamin B1. In these mice, it would be possible to ask: Does the production of lamin B1 from the *Lmnb2* locus prevent the neuropathology that is normally associated with lamin B2 deficiency? If the answer is “no,” that would imply that the two B-type lamins have distinct and nonredundant roles in brain development.

Recently, Yoon *et al.* [48] found that lamin B2, but not lamin A or lamin B1, is translated in *Xenopus* retinal ganglion cell (RGC) axons and that association of exonuclear lamin B2 with mitochondria is essential for RGC axon maintenance. The role of lamin B2, if any, in axon maintenance in mammals is unknown and should be investigated.

Regulation of the A-type lamins

LMNA expression is developmentally regulated; high levels of *LMNA* expression appear late in embryonic development and in differentiated cells. For this reason, the expression of lamins A and C has been used as a marker of stem cell differentiation [5, 49]. However, surprisingly little is known about mechanisms controlling the expression of *LMNA* during development. Lin *et al.* [50] observed that the proximal promoter of *LMNA* drives transcription in many cell types, including Burkitt lymphoma Raji cells (where A-type lamins are not expressed). These findings suggested that the *LMNA* promoter might be active in all cells and that distinct regulatory elements serve to silence *LMNA* expression in undifferentiated cells. Later, Tiwari *et al.* [51] showed that AP1 and SP1 sites in the 5′ promoter of rat *Lmna* are sufficient for the active transcription, and suggested that conformational changes in chromatin might underlie cell-type specific repression of *Lmna* expression.

DNase I hypersensitive sites, indicators of open chromatin structure, have been observed in the first intron of mouse *Lmna* [52]. When reporter constructs containing cell-type specific *Lmna* DNase I hypersensitive sites were stably integrated into the chromosomal DNA, transcription increased [52]. The methylation status of a CpG island in the *LMNA* promoter also appears to correlate with inactivation of *LMNA* in the setting of hematologic malignancies [53]. Agrelo *et al.* [53] found hypermethylation of a promoter CpG island of *LMNA* (as judged by bisulfite sequencing) in tumor cells from leukemias and lymphomas

patients, and they suggested that methylation could be responsible for the minimal expression of A-type lamins in those cells. Thus, the expression of A-type lamins may depend, at least in part, on epigenetic regulation of *LMNA*.

The fact that the expression of A-type lamins is activated late in development has prompted speculation that lamins A and C could play unique roles in differentiated cells [5, 6]. However, it is also conceivable that the expression of A-type lamins is suppressed in undifferentiated cells simply because these lamins are deleterious for embryonic development. At least in *Drosophila*, ectopic expression of lamin C leads to stage-specific lethality [54]. It would be worthwhile determining if ectopic expression of lamin A/C in early phases of development adversely affects mammalian development. For example, it would be interesting to express A-type lamins in undifferentiated cells at early stages of development by “knocking in” lamin A coding sequences into the *Lmnb1* locus. If mouse embryos heterozygous for this sort of knock-in allele failed to develop normally, it would imply that lamin A expression adversely affects embryonic development.

Regulation of lamin A expression in the brain by a microRNA

The health and vitality of *Lmna*^{LCO/LCO} [20], *Lmna*^{LAO/LAO} [21], and *Lmna*^{PLAO/PLAO} [22] have demonstrated that the loss of one of the two *Lmna* isoforms does not cause significant pathology. However, the vitality of these “single isoform” mouse models should not be interpreted as proof that the two isoforms lack unique functions. The preservation of the two protein isoforms during mammalian evolution represents strong evidence that the two proteins are important, and we are confident that unique functions for the two isoforms will eventually be uncovered.

Another reason to believe that the two protein isoforms have distinct properties comes from recent studies by Jung *et al.* [47], showing that the relative amounts of lamin A and lamin C can be quite different in different tissues. In most peripheral tissues, the levels of lamin A and C are similar, but the situation is quite different in the brain. By performing western blots of protein extracts from different tissues, Jung *et al.* [47] showed that the expression of lamin A is far lower in the central nervous system than in peripheral tissues, while the level of lamin C expression is similar (Figure 3a). By immunohistochemistry, lamin A expression is nearly absent in neurons and glia of the mouse brain, and the only cells that produce significant amounts of lamin A within the brain are capillary endothelial cells and meningeal cells (Figure 3b). Lamin C is expressed in all cell types within the adult brain. Similar findings were observed with *Zmpste24*-deficient mice, where the conversion of farnesyl-prelamin A to mature lamin A is blocked. The brains of those mice contain abundant amounts of lamin C but almost no prelamin A—except in capillary endothelial cells and the meninges. Studies of lamin C and prelamin A transcript levels yielded concordant results: lamin C transcript levels in the brain are high, while prelamin A transcript levels are low.

To understand the differential expression of lamin A and lamin C in the brain, Jung *et al.* [47] first examined the most likely explanation—a distinct pattern of mRNA splicing in the brain. They reasoned that if alternative splicing were the mechanism, then lamin A expression should be abundant in the central nervous system of lamin A-only mice (*Lmna*^{LAO/LAO}) [21]—where alternative splicing is absent and all of the output of the *Lmna* gene is channeled into prelamin A transcripts. But this was not the case! The amount of lamin A in the central nervous system of *Lmna*^{LAO/LAO} mice is extremely low, as judged by western blots analysis. Also, by immunohistochemistry, lamin A can be found in capillary endothelial cells within the brain of *Lmna*^{LAO/LAO} mice but is almost absent in neurons and glia. The same sorts of findings are observed in gene-targeted mice carrying a mutant *Lmna* allele that yields progerin, the mutant prelamin A found in patients with Hutchinson-Gilford

progeria syndrome. In that mouse model, high levels of progerin are found in peripheral tissues, but very little is found in the brain. Both of these mouse models show that the low levels of lamin A in the brain cannot be due to alternative splicing and instead must be due to another posttranscriptional mechanism.

Next, Jung *et al.* [47] examined prelamin A's 3' UTR and identified a putative binding site for miR-9, a brain specific microRNA [55–58]. To determine if miR-9 might downregulate lamin A expression, they expressed miR-9 in fibroblasts and HeLa cells. The expression of miR-9 reduced lamin A expression but had no effect on lamin C expression (Figure 3c). They [47] also showed that when the putative miR-9 binding motif in prelamin A's 3' UTR was mutated or deleted, miR-9 no longer downregulated prelamin A expression. Also, when the critical RNA-binding motif in the miR-9 expression vector was mutated, the ability of the mutant miR-9 to downregulate prelamin A expression was abolished [47]. Finally, Jung *et al.* [47] reported circumstantial evidence suggesting that microRNAs play a significant role in regulating lamin A expression *in vivo*. They generated forebrain-specific *Dicer* knockout mice [59, 60] (DICER is essential for the synthesis of microRNAs). As predicted, the level of lamin A protein in the forebrain-specific *Dicer* knockout mice increased in the forebrain but remained low in the cerebellum (where DICER is expressed normally) [47].

Reduced expression of lamin A in central nervous system neurons is not a peculiarity of the mouse. In a recent study, Wakabayashi *et al.* [61] examined the retina of the rat and found that retinal neurons express exclusively lamin C, while some of the surrounding cell types express both lamin A and lamin C. They speculated that the exclusive expression of lamin C in retinal neurons could be relevant to neuronal differentiation or gene expression.

Jung *et al.* [47] proposed that the elimination of prelamin A transcripts by miR-9 could explain why children with HGPS are spared from central nervous system disease. This explanation is both attractive and plausible, particularly since progerin levels are extremely low in the brains of *Lmna* knock-in mice expressing progerin [47]. However, one could argue that the brain might be spared from disease—even if it were to produce large amounts of progerin. Children with HGPS exhibit little or no pathology in the liver or kidney, even though those organs produce large amounts of progerin. Whether progerin expression is toxic to the brain needs to be tested with knock-in mice that produce progerin, rather than lamin C, in the brain.

In a recent paper, Nissan and coworkers [62] confirmed that miR-9 expression downregulates prelamin A expression in cultured cells, including neurons derived from induced pluripotent stem cells. When miR-9 was expressed in HGPS mesenchymal stem cells, progerin levels fell (relative to lamin C), and the percentage of cells with misshapen nuclei was slightly lower [62].

The studies by Jung *et al.* [47] and the subsequent studies by Nissan *et al.* [62] are certainly consistent with the idea that miR-9 is a key regulator of prelamin A/lamin A expression in the brain. However, it is important to remember that this conclusion has been supported mainly by *in vitro* studies in cultured cells. Also, the forebrain-specific *Dicer* knockout observations, while suggesting a role for microRNAs in prelamin A regulation, did not prove that miR-9 is solely responsible for prelamin A regulation. Mice lacking both miR-9-2 and miR-9-3 were recently characterized; these mice have severe neurodevelopmental abnormalities and die within 1 week [63]. Unfortunately, the expression of lamin A in these mice was not investigated. However, even if *miR-9-2/3* knockout mice had elevated levels of prelamin A transcripts and lamin A protein in the brain, the interpretation would not be straightforward, given that miR-9 targets many other genes, and some of those changes might lead to secondary changes in lamin A expression.

At this point, it would be highly desirable to test the significance of miR-9 with *Lmna* knock-in mice with a mutation in the miR-9 binding site in prelamins A's 3' UTR. The analysis of such a mouse model should reveal whether miR-9 is the *only* relevant factor in prelamins A regulation, or whether other factors are also involved.

The discovery that lamin A expression in the brain is regulated by a microRNA raises a number of issues for future research. One is whether the expression of lamin C in the brain serves an important function during postnatal life. The *Lmna*^{LAO/LAO} and *Lmna*^{PLAO/PLAO} mice have negligible levels of lamin A expression in neurons and glia yet have no obvious pathology in the brain. However, it is possible that in-depth characterization of those mice would uncover behavioral and cognitive abnormalities. Another issue is why the mouse, and apparently the rat also, have evolved a mechanism to limit the expression of lamin A in the brain. Would the expression of lamin A in neurons and glia, rather than lamin C, be associated with neuropathology or defects in cognition? To address that issue, it would be necessary to generate a mouse model where neurons produce lamin A. Presumably, one could accomplish this goal by creating *Lmna* knock-in mice where prelamins A's 3' UTR was replaced with lamin C's 3' UTR. A final issue is whether robust downregulation of prelamins A transcripts occurs in the *human* brain. Indirect observations suggest that this could be the case: the miR-9 binding site is conserved in the human *LMNA* gene, and the levels of lamin A are far lower than the levels of lamin C in neuronal cells derived from human induced pluripotent stem cells [64]. In the future, it would be very interesting to assess lamin A and lamin C expression, along with miR-9 expression levels, in the brains of human fetuses, infants, children, and adults of various ages.

Nuclear lamins and human disease

A-type lamins have been linked to multiple human genetic diseases, including cardiomyopathy, several forms of muscular dystrophy, peripheral neuropathy, partial lipodystrophy, mandibuloacral dysplasia, and Hutchinson-Gilford progeria syndrome (HGPS) [2, 3, 19]. Thus far, more than 200 clinically significant missense, nonsense, frameshift, and splicing mutations in *LMNA* have been described (<http://www.umd.be>) [65]. The "A-type lamin diseases" largely affect mesenchymal tissues, and none of them, as far as we are aware, causes primary disease within the central nervous system.

The sole *bona fide* link of B-type lamins to human disease is an adult-onset autosomal dominant leukodystrophy (ADLD), which is caused by a duplication of *LMNB1* [66–68]. This demyelinating disorder, which is sometimes mistaken for a progressive form of multiple sclerosis, was first identified in 1984 in a large American-Irish family but has since been found in multiple kindreds around the world [69]. The disease generally presents in middle-aged years with autonomic dysfunction, followed by the development of progressive cerebellar and pyramidal tract abnormalities [70]. MRI scans show widespread symmetrical demyelination in the white matter, beginning in the frontoparietal area and extending to the brain stem and cerebellum [71–73]. Light microscopy shows vacuolization of the white matter with preservation of oligodendrocytes, and no evidence of inflammation. Abnormalities of the neurons or axons are minimal or absent [72, 73]. The locus for this disease was mapped to the long arm of chromosome 5 (near 5q31) by the laboratory of Dr. Ying-Hui Fu at the University of California, San Francisco. Later, the same group showed that ADLD is caused by a duplication of *LMNB1* on chromosome 5 [66]. The size of the duplicated stretch of genomic DNA is variable in different kindreds. Increased expression of lamin B1 in ADLD patients has been documented both in the brain [66] and in peripheral blood leukocytes [74].

In one family with ADLD but without autonomic disease, the disease locus was mapped to 5q23.2–q23.3, which contains 11 genes including *LMNB1* [75]. No mutations were found in the coding regions of these genes, nor were there any gene duplications; nevertheless, the expression of lamin B1 in lymphoblastoid cell lines from affected patients was higher than in cell lines from healthy controls. The authors speculated that the ADLD in this kindred might be due to a mutation in a regulatory element that leads to increased *LMNB1* expression [75].

Thus far, no mouse model of ADLD has been generated. However, important clues regarding disease pathogenesis have been uncovered with cell culture studies. Overexpression of lamin B1 in neuronal, astrocytic, and oligodendrocytic cell lines results in misshapen cell nuclei, and fibroblasts that overexpressed lamin B1 have abnormalities in the localization of heterochromatin protein 1 β and methylated histone 3 [76]. Also, overexpression of *LMNB1* in an oligodendrocyte cell line represses transcription of oligodendrocyte-specific genes such as myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein [76]. Finally, expression of human *LMNB1* in the eye of *Drosophila* leads to degenerative abnormalities in the eye, including pigment loss, roughening of the eye, and reduced eye size [66].

The expression of lamin B1 is downregulated by a microRNA, miR-23, which binds to lamin B1's 3' UTR [76]. Therefore, miR-23 has the potential to reverse the adverse effects of lamin B1 on oligodendrocyte gene expression, and indeed the expression of miR-23 did enhance oligodendrocyte differentiation in cultures of glial cells [76]. Interestingly, the expression pattern of miR-23 is the opposite of that of lamin B1. Lamin B1 levels peak late in development and decline in postnatal life; miR-23 levels are low during embryonic development and higher in postnatal life [76].

Currently, it is unclear why overexpression of lamin B1 leads to a demyelinating disease with adverse effects on oligodendrocyte gene expression, whereas a deficiency of lamin B1 leads to defects in neuronal migration and neuronal survival. Presumably, altered expression of lamin B1 changes the composition of the nuclear lamina, leading to secondary changes in gene expression and protein–protein interactions. The consequences of these changes are likely to be distinct in different cell types. In any case, the finding of ADLD with *LMNB1* gene duplications [71–73], together with the neuropathology in *Lmnbl* and *Lmnbl2* knockout mice [41, 42], underscores the importance of B-type lamins in brain development and homeostasis.

There have been no reports of *LMNB1* or *LMNB2* nonsense, frameshift, splicing, or missense mutations. Heterozygosity for *Lmnbl* or *Lmnbl2* knockout mutations does not appear to cause neurodevelopmental abnormalities. Whether half-normal amounts of lamin B1 or lamin B2 synthesis would alter gene expression in neurons or glia later in life has never been evaluated. Given the phenotypes of the knockout mice, *homozygous* loss of *LMNB1* or *LMNB2* in humans would likely lead to severe defects in the development of the brain. We predict that homozygous mutations in B-type lamins will eventually be uncovered in human fetuses with defects in neuronal migration and neuronal survival. Neuronal migration abnormalities have also been implicated in the pathogenesis of milder forms of neurological disease, such as epilepsy and autism [77, 78]. We would not be surprised if human geneticists ultimately uncover *LMNB1* or *LMNB2* missense mutations in patients with familial forms of those diseases.

Perspectives

Recent discoveries on the role of the B-type lamins in the brain [41, 42] open a new window on mechanisms underlying neuronal migration and brain development. Finding a role for

nuclear lamins in brain development has raised the possibility that genetic defects in *LMNB1* and *LMNB2* could cause neurodevelopmental abnormalities in humans. Also, the discovery that prelamin A expression in the brain is regulated by a microRNA [47] suggests that lamins A and C could have distinct functions in the brain.

The study of nuclear lamins in the central nervous system is an exciting new area of research, but our understanding of this topic is still quite limited. To better define the function of nuclear lamins in the brain, more studies with knock-in mouse models are necessary (as has been suggested repeatedly in the course of this review article). Also, we believe that the human genetics of B-type lamins needs more attention. It seems likely, based on the findings in knockout mice [41, 42], that *LMNB1* and *LMNB2* mutations will eventually be uncovered in humans with neurodevelopmental abnormalities.

Acknowledgments

This work was supported by the National Institutes of Health Grants HL86683 (LGF), HL089781 (LGF), HL76839 (SGY), and AG035626-09 (SGY).

References

1. Melcer S, Gruenbaum Y, Krohne G. Invertebrate lamins. *Exp Cell Res*. 2007; 313:2157–2166.10.1016/j.yexcr.2007.03.004 [PubMed: 17451683]
2. Broers JL, Ramaekers FC, Bonne G, Yaou RB, Hutchison CJ. Nuclear lamins: laminopathies and their role in premature ageing. *Physiol Rev*. 2006; 86:967–1008.10.1152/physrev.00047.2005 [PubMed: 16816143]
3. Worman HJ. Nuclear lamins and laminopathies. *J Pathol*. 2012; 226:316–325.10.1002/path.2999 [PubMed: 21953297]
4. Dittmer TA, Misteli T. The lamin protein family. *Genome Biol*. 2011; 12:222.10.1186/gb-2011-12-5-222 [PubMed: 21639948]
5. Rober RA, Weber K, Osborn M. Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. *Development*. 1989; 105:365–378. [PubMed: 2680424]
6. Lebel S, Lampron C, Royal A, Raymond Y. Lamins A and C appear during retinoic acid-induced differentiation of mouse embryonal carcinoma cells. *J Cell Biol*. 1987; 105:1099–1104. [PubMed: 3654748]
7. Lin F, Worman HJ. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. *J Biol Chem*. 1993; 268:16321–16326. [PubMed: 8344919]
8. Lin F, Worman HJ. Structural organization of the human gene (*LMNB1*) encoding nuclear lamin B1. *Genomics*. 1995; 27:230–236.10.1006/geno.1995.1036 [PubMed: 7557986]
9. Biamonti G, Giacca M, Perini G, Contreas G, Zentilin L, Weighardt F, Guerra M, Della Valle G, Saccone S, Riva S, et al. The gene for a novel human lamin maps at a highly transcribed locus of chromosome 19 which replicates at the onset of S-phase. *Mol Cell Biol*. 1992; 12:3499–3506. [PubMed: 1630457]
10. Erber A, Riemer D, Hofemeister H, Bovenschulte M, Stick R, Panopoulou G, Lehrach H, Weber K. Characterization of the Hydra lamin and its gene: A molecular phylogeny of metazoan lamins. *J Mol Evol*. 1999; 49:260–271.10.1007/PL00006548 [PubMed: 10441677]
11. Davies, BS.; Coffinier, C.; Yang, SH.; Jung, HJ.; Fong, LG.; Young, SG. Posttranslational processing of nuclear lamins. In: Tamanoi, F.; Hrycyna, CA.; Bergo, MO., editors. *The Enzymes*. Elsevier; Amsterdam: 2011. p. 21–41.
12. Fisher DZ, Chaudhary N, Blobel G. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. *Proc Natl Acad Sci U S A*. 1986; 83:6450–6454. [PubMed: 3462705]

13. McKeon FD, Kirschner MW, Caput D. Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins. *Nature*. 1986; 319:463–468. 10.1038/319463a0. [PubMed: 3453101]
14. Heitlinger E, Peter M, Lustig A, Villiger W, Nigg EA, Aebi U. The role of the head and tail domain in lamin structure and assembly: analysis of bacterially expressed chicken lamin A and truncated B2 lamins. *J Struct Biol*. 1992; 108:74–89. 1047-8477(92)90009-Y. [PubMed: 1562436]
15. Sullivan T, Escalante-Alcalde D, Bhatt H, Anver M, Bhat N, Nagashima K, Stewart CL, Burke B. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. *J Cell Biol*. 1999; 147:913–920. [PubMed: 10579712]
16. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, Stewart CL, Lee RT. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. *J Clin Invest*. 2004; 113:370–378. 10.1172/JCI19670 [PubMed: 14755334]
17. Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, Toniolo D. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. *Nat Genet*. 1994; 8:323–327. 10.1038/ng1294-323 [PubMed: 7894480]
18. Ellis JA, Craxton M, Yates JR, Kendrick-Jones J. Aberrant intracellular targeting and cell cycle-dependent phosphorylation of emerin contribute to the Emery-Dreifuss muscular dystrophy phenotype. *J Cell Sci*. 1998; 111 (Pt 6):781–792. [PubMed: 9472006]
19. Worman HJ, Fong LG, Muchir A, Young SG. Laminopathies and the long strange trip from basic cell biology to therapy. *J Clin Invest*. 2009; 119:1825–1836. 10.1172/JCI37679 [PubMed: 19587457]
20. Fong LG, Ng JK, Lammerding J, Vickers TA, Meta M, Cote N, Gavino B, Qiao X, Chang SY, Young SR, Yang SH, Stewart CL, Lee RT, Bennett CF, Bergo MO, Young SG. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. *J Clin Invest*. 2006; 116:743–752. 10.1172/JCI27125 [PubMed: 16511604]
21. Coffinier C, Jung HJ, Li Z, Nobumori C, Yun UJ, Farber EA, Davies BS, Weinstein MM, Yang SH, Lammerding J, Farahani JN, Bentolila LA, Fong LG, Young SG. Direct synthesis of lamin A, bypassing prelamin A processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. *J Biol Chem*. 2010; 285:20818–20826. 10.1074/jbc.M110.128835 [PubMed: 20439468]
22. Davies BS, Barnes RH 2nd, Tu Y, Ren S, Andres DA, Spielmann HP, Lammerding J, Wang Y, Young SG, Fong LG. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. *Hum Mol Genet*. 2010; 19:2682–2694. 10.1093/hmg/ddq158 [PubMed: 20421363]
23. Davies BS, Coffinier C, Yang SH, Barnes RH 2nd, Jung HJ, Young SG, Fong LG. Investigating the purpose of prelamin A processing. *Nucleus*. 2011; 2:4–9. 10.4161/nucl.2.1.13723 [PubMed: 21647293]
24. Davies BS, Fong LG, Yang SH, Coffinier C, Young SG. The posttranslational processing of prelamin A and disease. *Annu Rev Genomics Hum Genet*. 2009; 10:153–174. 10.1146/annurev-genom-082908-150150 [PubMed: 19453251]
25. Hennekes H, Nigg EA. The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. *J Cell Sci*. 1994; 107 (Pt 4):1019–1029. [PubMed: 8056827]
26. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, Mohr A, Meta M, Genant H, Jiang Y, Wisner ER, Van Bruggen N, Carano RA, Michaelis S, Griffey SM, Young SG. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. *Proc Natl Acad Sci U S A*. 2002; 99:13049–13054. 10.1073/pnas.192460799 [PubMed: 12235369]
27. Pendas AM, Zhou Z, Cadinanos J, Freije JM, Wang J, Hultenby K, Astudillo A, Wernerson A, Rodriguez F, Tryggvason K, Lopez-Otin C. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. *Nat Genet*. 2002; 31:94–99. 10.1038/ng871 [PubMed: 11923874]
28. Moulson CL, Go G, Gardner JM, van der Wal AC, Smitt JH, van Hagen JM, Miner JH. Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy

- restrictive dermopathy. *J Invest Dermatol.* 2005; 125:913–919.10.1111/j.0022-202X.2005.23846.x [PubMed: 16297189]
29. Navarro CL, Cadinanos J, De Sandre-Giovannoli A, Bernard R, Courrier S, Boccaccio I, Boyer A, Kleijer WJ, Wagner A, Giuliano F, Beemer FA, Freije JM, Cau P, Hennekam RC, Lopez-Otin C, Badens C, Levy N. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. *Hum Mol Genet.* 2005; 14:1503–1513.10.1093/hmg/ddi159 [PubMed: 15843403]
 30. Fong LG, Ng JK, Meta M, Cote N, Yang SH, Stewart CL, Sullivan T, Burghardt A, Majumdar S, Reue K, Bergo MO, Young SG. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. *Proc Natl Acad Sci U S A.* 2004; 101:18111–18116.10.1073/pnas.0408558102 [PubMed: 15608054]
 31. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Levy N. Lamin A truncation in Hutchinson-Gilford progeria. *Science.* 2003; 300:2055.10.1126/science.1084125 [PubMed: 12702809]
 32. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. *Nature.* 2003; 423:293–298.10.1038/nature01629 [PubMed: 12714972]
 33. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. *J Cell Sci.* 2001; 114:4557–4565. [PubMed: 11792820]
 34. Belmont AS, Zhai Y, Thilenius A. Lamin B distribution and association with peripheral chromatin revealed by optical sectioning and electron microscopy tomography. *J Cell Biol.* 1993; 123:1671–1685. [PubMed: 8276889]
 35. Tsai MY, Wang S, Heidinger JM, Shumaker DK, Adam SA, Goldman RD, Zheng Y. A mitotic lamin B matrix induced by RanGTP required for spindle assembly. *Science.* 2006; 311:1887–1893.10.1126/science.1122771 [PubMed: 16543417]
 36. Moir RD, Montag-Lowy M, Goldman RD. Dynamic properties of nuclear lamins: lamin B is associated with sites of DNA replication. *J Cell Biol.* 1994; 125:1201–1212. [PubMed: 7911470]
 37. Tang CW, Maya-Mendoza A, Martin C, Zeng K, Chen S, Feret D, Wilson SA, Jackson DA. The integrity of a lamin-B1-dependent nucleoskeleton is a fundamental determinant of RNA synthesis in human cells. *J Cell Sci.* 2008; 121:1014–1024.10.1242/jcs.020982 [PubMed: 18334554]
 38. Yang SH, Chang SY, Yin L, Tu Y, Hu Y, Yoshinaga Y, de Jong PJ, Fong LG, Young SG. An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and hair. *Hum Mol Genet.* 2011; 20:3537–3544.10.1093/hmg/ddr266 [PubMed: 21659336]
 39. Yang SH, Jung HJ, Coffinier C, Fong LG, Young SG. Are B-type lamins essential in all mammalian cells? *Nucleus.* 2011; 2:562–569.10.4161/nucl.2.6.18085 [PubMed: 22127257]
 40. Kim Y, Sharov AA, McDole K, Cheng M, Hao H, Fan CM, Gaiano N, Ko MS, Zheng Y. Mouse B-type lamins are required for proper organogenesis but not by embryonic stem cells. *Science.* 2011; 334:1706–1710.10.1126/science.1211222 [PubMed: 22116031]
 41. Coffinier C, Chang SY, Nobumori C, Tu Y, Farber EA, Toth JI, Fong LG, Young SG. Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiency. *Proc Natl Acad Sci U S A.* 2010; 107:5076–5081.10.1073/pnas.0908790107 [PubMed: 20145110]
 42. Coffinier C, Jung HJ, Nobumori C, Chang S, Tu Y, Barnes RH 2nd, Yoshinaga Y, de Jong PJ, Vergnes L, Reue K, Fong LG, Young SG. Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. *Mol Biol Cell.* 2011; 22:4683–4693.10.1091/mbc.E11-06-0504 [PubMed: 21976703]
 43. Solecki DJ, Govek EE, Tomoda T, Hatten ME. Neuronal polarity in CNS development. *Genes Dev.* 2006; 20:2639–2647.10.1101/gad.1462506 [PubMed: 17015428]
 44. Salina D, Bodoor K, Eckley DM, Schroer TA, Rattner JB, Burke B. Cytoplasmic dynein as a facilitator of nuclear envelope breakdown. *Cell.* 2002; 108:97–107.10.1016/S0092-8674(01)00628-6 [PubMed: 11792324]

45. Vergnes L, Peterfy M, Bergo MO, Young SG, Reue K. Lamin B1 is required for mouse development and nuclear integrity. *Proc Natl Acad Sci U S A*. 2004; 101:10428–10433.10.1073/pnas.0401424101 [PubMed: 15232008]
46. Gorski JA, Talley T, Qiu M, Puellas L, Rubenstein JL, Jones KR. Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. *J Neurosci*. 2002; 22:6309–6314. [PubMed: 12151506]
47. Jung HJ, Coffinier C, Choe Y, Beigneux AP, Davies BS, Yang SH, Barnes RH 2nd, Hong J, Sun T, Pleasure SJ, Young SG, Fong LG. Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. *Proc Natl Acad Sci U S A*. 2012; 109:E423–431.10.1073/pnas.1111780109 [PubMed: 22308344]
48. Yoon BC, Jung H, Dwivedy A, O'Hare CM, Zivraj KH, Holt CE. Local translation of extranuclear lamin B promotes axon maintenance. *Cell*. 2012; 148:752–764.10.1016/j.cell.2011.11.064 [PubMed: 22341447]
49. Constantinescu D, Gray HL, Sammak PJ, Schatten GP, Csoka AB. Lamin A/C expression is a marker of mouse and human embryonic stem cell differentiation. *Stem Cells*. 2006; 24:177–185.10.1634/stemcells.2004-0159 [PubMed: 16179429]
50. Lin F, Worman HJ. Expression of nuclear lamins in human tissues and cancer cell lines and transcription from the promoters of the lamin A/C and B1 genes. *Exp Cell Res*. 1997; 236:378–384.10.1006/excr.1997.3735 [PubMed: 9367621]
51. Tiwari B, Muralikrishna B, Parnaik VK. Functional analysis of the 5' promoter region of the rat lamin A gene. *DNA Cell Biol*. 1998; 17:957–965. [PubMed: 9839805]
52. Nakamachi K, Nakajima N. DNase I hypersensitive sites and transcriptional activation of the lamin A/C gene. *Eur J Biochem*. 2000; 267:1416–1422.10.1046/j.1432-1327.2000.01135.x [PubMed: 10691979]
53. Agrelo R, Setien F, Espada J, Artiga MJ, Rodriguez M, Perez-Rosado A, Sanchez-Aguilera A, Fraga MF, Piris MA, Esteller M. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. *J Clin Oncol*. 2005; 23:3940–3947.10.1200/JCO.2005.11.650 [PubMed: 15867203]
54. Stuurman N, Delbecq JP, Callaerts P, Aebi U. Ectopic overexpression of Drosophila lamin C is stage-specific lethal. *Exp Cell Res*. 1999; 248:350–357.10.1006/excr.1999.4396 [PubMed: 10222127]
55. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. *Curr Biol*. 2002; 12:735–739.10.1016/S0960-9822(02)00809-6 [PubMed: 12007417]
56. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of microRNAs during brain development. *RNA*. 2003; 9:1274–1281. [PubMed: 13130141]
57. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. *Genome Biol*. 2004; 5:R13.10.1186/gb-2004-5-3-r13 [PubMed: 15003116]
58. Gao FB. Context-dependent functions of specific microRNAs in neuronal development. *Neural Dev*. 2010; 5:25.10.1186/1749-8104-5-25 [PubMed: 20920300]
59. Murchison EP, Partridge JF, Tam OH, Cheloufi S, Hannon GJ. Characterization of Dicer-deficient murine embryonic stem cells. *Proc Natl Acad Sci U S A*. 2005; 102:12135–12140.10.1073/pnas.0505479102 [PubMed: 16099834]
60. Kawase-Koga Y, Otaegi G, Sun T. Different timings of Dicer deletion affect neurogenesis and gliogenesis in the developing mouse central nervous system. *Dev Dyn*. 2009; 238:2800–2812.10.1002/dvdy.22109 [PubMed: 19806666]
61. Wakabayashi T, Mori T, Hirahara Y, Koike T, Kubota Y, Takamori Y, Yamada H. Nuclear lamins are differentially expressed in retinal neurons of the adult rat retina. *Histochem Cell Biol*. 2011; 136:427–436.10.1007/s00418-011-0853-8 [PubMed: 21842415]

62. Nissan X, Biondel S, Navarro C, Maury Y, Denis C, Girard M, Martinat C, De Sandre-Giovannoli A, Levy N, Peschanski M. Unique preservation of neural cells in Hutchinson-Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA. *Cell Reports*. 2012; 1:1–9.10.1016/j.celrep.2012.05.015 [PubMed: 22832102]
63. Shibata M, Nakao H, Kiyonari H, Abe T, Aizawa S. MicroRNA-9 regulates neurogenesis in mouse telencephalon by targeting multiple transcription factors. *J Neurosci*. 2011; 31:3407–3422.10.1523/JNEUROSCI.5085-10.2011 [PubMed: 21368052]
64. Zhang J, Lian Q, Zhu G, Zhou F, Sui L, Tan C, Mutalif RA, Navasankari R, Zhang Y, Tse HF, Stewart CL, Colman A. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. *Cell Stem Cell*. 2011; 8:31–45.10.1016/j.stem.2010.12.002 [PubMed: 21185252]
65. Stewart CL, Kozlov S, Fong LG, Young SG. Mouse models of the laminopathies. *Exp Cell Res*. 2007; 313:2144–2156.10.1016/j.yexcr.2007.03.026 [PubMed: 17493612]
66. Padiath QS, Saigoh K, Schiffmann R, Asahara H, Yamada T, Koeppen A, Hogan K, Ptacek LJ, Fu YH. Lamin B1 duplications cause autosomal dominant leukodystrophy. *Nat Genet*. 2006; 38:1114–1123.10.1038/ng1872 [PubMed: 16951681]
67. Brussino A, Vaula G, Cagnoli C, Mauro A, Pradotto L, Daniele D, Di Gregorio E, Barberis M, Arduino C, Squadrone S, Abete MC, Migone N, Calabrese O, Brusco A. A novel family with Lamin B1 duplication associated with adult-onset leucoencephalopathy. *J Neurol Neurosurg Psychiatry*. 2009; 80:237–240.10.1136/jnnp.2008.147330 [PubMed: 19151023]
68. Meijer IA, Simoes-Lopes AA, Laurent S, Katz T, St-Onge J, Verlaan DJ, Dupre N, Thibault M, Mathurin J, Bouchard JP, Rouleau GA. A novel duplication confirms the involvement of 5q23.2 in autosomal dominant leukodystrophy. *Arch Neurol*. 2008; 65:1496–1501.10.1001/archneur.65.11.1496 [PubMed: 19001169]
69. Eldridge R, Anayiotos CP, Schlesinger S, Cowen D, Bever C, Patronas N, McFarland H. Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. *N Engl J Med*. 1984; 311:948–953. [PubMed: 6472420]
70. Schwankhaus JD, Katz DA, Eldridge R, Schlesinger S, McFarland H. Clinical and pathological features of an autosomal dominant, adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. *Arch Neurol*. 1994; 51:757–766. [PubMed: 8042923]
71. Bergui M, Bradac GB, Leombruni S, Vaula G, Quattrocchio G. MRI and CT in an autosomal-dominant, adult-onset leukodystrophy. *Neuroradiology*. 1997; 39:423–426. [PubMed: 9225322]
72. Coffeen CM, McKenna CE, Koeppen AH, Plaster NM, Maragakis N, Mihalopoulos J, Schwankhaus JD, Flanigan KM, Gregg RG, Ptacek LJ, Fu YH. Genetic localization of an autosomal dominant leukodystrophy mimicking chronic progressive multiple sclerosis to chromosome 5q31. *Hum Mol Genet*. 2000; 9:787–793.10.1093/hmg/9.5.787 [PubMed: 10749986]
73. Melberg A, Hallberg L, Kalimo H, Raininko R. MR characteristics and neuropathology in adult-onset autosomal dominant leukodystrophy with autonomic symptoms. *AJNR Am J Neuroradiol*. 2006; 27:904–911. [PubMed: 16611789]
74. Schuster J, Sundblom J, Thuresson AC, Hassin-Baer S, Klopstock T, Dichgans M, Cohen OS, Raininko R, Melberg A, Dahl N. Genomic duplications mediate overexpression of lamin B1 in adult-onset autosomal dominant leukodystrophy (ADLD) with autonomic symptoms. *Neurogenetics*. 2011; 12:65–72.10.1007/s10048-010-0269-y [PubMed: 21225301]
75. Brussino A, Vaula G, Cagnoli C, Panza E, Seri M, Di Gregorio E, Scappaticci S, Camanini S, Daniele D, Bradac GB, Pinessi L, Cavalieri S, Grosso E, Migone N, Brusco A. A family with autosomal dominant leukodystrophy linked to 5q23.2-q23.3 without lamin B1 mutations. *Eur J Neurol*. 2010; 17:541–549.10.1111/j.1468-1331.2009.02844.x [PubMed: 19961535]
76. Lin ST, Fu YH. miR-23 regulation of lamin B1 is crucial for oligodendrocyte development and myelination. *Dis Model Mech*. 2009; 2:178–188.10.1242/dmm.001065 [PubMed: 19259393]
77. Deutsch SI, Burket JA, Katz E. Does subtle disturbance of neuronal migration contribute to schizophrenia and other neurodevelopmental disorders? Potential genetic mechanisms with possible treatment implications. *Eur Neuropsychopharmacol*. 2010; 20:281–287.10.1016/j.euroneuro.2010.02.005 [PubMed: 20207112]

78. Wegiel J, Kuchna I, Nowicki K, Imaki H, Marchi E, Ma SY, Chauhan A, Chauhan V, Bobrowicz TW, de Leon M, Louis LA, Cohen IL, London E, Brown WT, Wisniewski T. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. *Acta Neuropathol.* 2010; 119:755–770.10.1007/s00401-010-0655-4 [PubMed: 20198484]

\$watermark-text

\$watermark-text

\$watermark-text

Figure 1.

Schematic diagram of nuclear lamin genes and nuclear lamin structure. All nuclear lamins have α -helical central rod domains (in grey) flanked by globular head and tail domains. The tail domains contain a nuclear localization signal (NLS, in red). Prelamin A (664 amino acids) and lamin C (572 amino acids) are alternatively spliced products of a single gene, *LMNA*. Lamin C terminates with exon 10 sequences and contains 6 unique amino acids at its carboxyl terminus (in green); prelamins A contains sequences from exons 11 and 12 and contains 98 unique amino acids at its carboxyl terminus (in sky blue). The 3' UTR for lamin C is yellow; the 3' UTRs for the other nuclear lamins are purple. The 5' UTRs are colored orange. Lamin A (646 amino acids) is formed from prelamins A by a series of four posttranslational processing events and involves the removal of the final 18 amino acids of prelamins A. Lamin B1 (586 amino acids) and lamin B2 (600 amino acids) are produced from independent genes, *LMNB1* and *LMNB2*, respectively. All of the lamins, except lamin C, contain a carboxyl-terminal *CaaX* motif, which triggers protein farnesylation. The farnesylated segment of prelamins A (in sky blue with blue stripes) is removed during the biogenesis of mature lamin A.

Figure 2.

Brain abnormalities in *Lmnb1* and *Lmnb2* knockout mice. *a*, Immunostaining of cerebral cortex from wild-type (*Lmnb2*^{+/+}) and *Lmnb2* knockout embryos (*Lmnb2*^{-/-}) at E16.5 with an antibody against lamin B1 (green). Arrowheads indicate “comet-shaped” nuclei. *b*, Immunostaining of cerebral cortex from *Lmnb1*^{+/+} and *Lmnb1* knockout embryos (*Lmnb1*^{Δ/Δ}) at E16.5 with an antibody against lamin B2 (green). Arrowheads indicate solitary blebs and asymmetric distribution of lamin B2. *c*, Hematoxylin and eosin staining of coronal brain sections from control (*Lmnb1*^{fl/fl} *Lmnb2*^{fl/fl}) and forebrain-specific *Lmnb1*/*Lmnb2* double knockout mice (*Emx1-Cre* *Lmnb1*^{fl/fl} *Lmnb2*^{fl/fl}). In the double knockout brain, the hippocampus and the cortex are nearly absent. Reproduced with permission from Coffinier *et al.* [42].

Figure 3.

Exclusive expression of lamin C in the mouse brain and downregulation of lamin A expression by miR-9, a brain-specific microRNA. *a*, Western blot of tissue extracts from a WT ($Lmna^{+/+}$) mouse and a $Lmna$ knockout ($Lmna^{-/-}$) mouse. Lamins A and C are expressed highly in the peripheral tissues (liver, heart, and kidney) of wild-type mice, whereas the brain (cerebellum and cortex) expresses mainly lamin C and little lamin A. *b*, Immunostaining of the liver and the cerebellum from WT mouse with antibodies against lamin A (red) and lamin C (green). DNA was stained with DAPI (blue). The liver expresses both lamin A and lamin C, whereas expression of lamin A in the brain is largely restricted to vascular endothelium cells. Neurons in the granular layers of cerebellum expresses lamin C. *c*, Reduced expression of lamin A in HeLa cells transfected with a miR-9 expression vector. Lamin C expression was unaffected. Transfected cells were readily identified by GFP expression (arrowheads). Expression of lamin A was not affected when cells were transfected with a control expression vector. Reproduced with permission from Jung *et al.* [47].